Pradžia › Navikai pagal histologinį tipą › Texas
Navikai pagal histologinį tipą klinikiniai tyrimai Texas
6 tyrimai dėl Navikai pagal histologinį tipą ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- UT Southwestern Medical Center, Dallas
- The University of Texas M.D. Anderson Cancer Center, Houston
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT05874921HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
36 Months – 22 Years · Visoms lytims · Atnaujinta 2026-09-04 · NCT03911388Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-29 · NCT04198766Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Texas Oncology - Austin Central, Austin
- World Research Link, Baytown
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-04 · NCT06463665A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-05-27 · NCT03093116Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.